Correlation between Serum Erythropoietin and Cerebral Collateral Flow in Acute Ischemic Stroke Patient
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Erythropoietin (EPO), which is associated with anemia, exerts neuroprotective effects in ischemic stroke. In cases of stenosis or narrowing of the main cerebral blood vessel, the prognosis is favorable if collateral blood circulation is well developed in acute stroke. Several studies have investigated the relationship between EPO administration and stroke outcomes. The present study investigated the correlation between serum EPO level and cerebral collateral circulation, which could result in favorable clinical outcomes.Methods: The study subjects were patients diagnosed with acute ischemic stroke who underwent initial brain magnetic resonance imaging between January 2020 and March 2022. Following brain computed tomography per-fusion for collateral flow, serum EPO levels were measured. Collaterals were assessed according to the Mass system and divided into good collateral (GC) or poor collateral (PC) groups. Serum EPO levels were determined using a chemiluminescence immunoassay method. A correlation coefficient analysis was conducted to determine the cor-relation between serum EPO levels and GC. A receiver operating characteristic curve analysis determined the cut-off value of EPO for GC.Results: Serum EPO levels were significantly higher in the GC than that in the PC group (P<0.05). The cut-off level of serum EPO for a good outcome was 9.1 mIU/mL.Conclusion: A high serum EPO (>9.1 mIU/mL) could be a marker of GC in patients with acute ischemic stroke that predicts good clinical outcomes.
Abstract
Background: Erythropoietin (EPO), which is associated with anemia, exerts neuroprotective effects in ischemic stroke. In cases of stenosis or narrowing of the main cerebral blood vessel, the prognosis is favorable if collateral blood circulation is well developed in acute stroke. Several studies have investigated the relationship between EPO administration and stroke outcomes. The present study investigated the correlation between serum EPO level and cerebral collateral circulation, which could result in favorable clinical outcomes.Methods: The study subjects were patients diagnosed with acute ischemic stroke who underwent initial brain magnetic resonance imaging between January 2020 and March 2022. Following brain computed tomography per-fusion for collateral flow, serum EPO levels were measured. Collaterals were assessed according to the Mass system and divided into good collateral (GC) or poor collateral (PC) groups. Serum EPO levels were determined using a chemiluminescence immunoassay method. A correlation coefficient analysis was conducted to determine the cor-relation between serum EPO levels and GC. A receiver operating characteristic curve analysis determined the cut-off value of EPO for GC.Results: Serum EPO levels were significantly higher in the GC than that in the PC group (P<0.05). The cut-off level of serum EPO for a good outcome was 9.1 mIU/mL.Conclusion: A high serum EPO (>9.1 mIU/mL) could be a marker of GC in patients with acute ischemic stroke that predicts good clinical outcomes.
참고문헌 (17)
- Aberg ND, "Serum erythropoietin and outcome after ischaemic stroke : a prospective study", BMJ Open, 6, pp.e009827~ (2016)
- Malhotra S, "Ischemic preconditioning is mediated by erythropoietin through PI-3 kinase signaling in an animal model of transient ischemic attack", J Neurosci Res, 83, pp.19~27 (2006)
- Liebeskind DS, "Collateral circulation in symptomatic intracranial atherosclerosis", J Cereb Blood Flow Metab, 31, pp.1293~1301 (2011)
- Maas MB, "Collateral vessels on CT angiography predict outcome in acute ischemic stroke", Stroke, 40, pp.3001~3005 (2009)
- Noguchi CT, "Survival and proliferative roles of erythropoietin beyond the erythroid lineage", Expert Rev Mol Med, 10, pp.e36~ (2008)
- Siren AL, "Erythropoietin and erythropoietin receptor in human ischemic", hypoxic brain, 2001, pp.101, 271~276
- Yip HK, "Effect of erythropoietin on level of circulating endothelial progenitor cells and outcome in patients after acute ischemic stroke", Crit Care, 15, pp.R40~ (2011)
- Lin L, "Perfusion computed tomography accurately quantifies collateral flow after acute ischemic stroke", Stroke, 51, pp.1006~1009 (2020)
- Yuksel IO, "Erythropoietin stimulates the coronary collateral development in patients with coronary chronic total occlusion", Neth Heart J, 24, pp.609~616 (2016)
- Erslev AJ, "Erythropoietin", N Engl J Med, 324, pp.1339~1344 (1991)
- Ma Y, "The effect of erythropoietin and its derivatives on ischemic stroke therapy : a comprehensive review", Front Pharmacol, 13, pp.743926~ (2022)
- Schuster SJ, "Erythropoietin : physiologic basis for clinical applications", Vox Sang, 65, pp.169~179 (1993)
- Ribatti D, "Erythropoietin as an angiogenic factor", Eur J Clin Invest, 33, pp.891~896 (2003)
- Carlini RG, "Recombinant human erythropoietin stimulates angiogenesis in vitro", Kidney Int, 47, pp.740~745 (1995)
- Wang L, "Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats", Stroke, 35, pp.1732~1737 (2004)
- Jerndal M, "A systematic review and meta-analysis of erythropoietin in experimental stroke", J Cereb Blood Flow Metab, 30, pp.961~968 (2010)
- Ginsberg MD, "The cerebral collateral circulation : relevance to pathophysiology and treatment of stroke", Neuropharmacology, 134(Pt B), pp.280~292 (2018)